ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Neurology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

14,556Medicare Part D Prescriptions Filled, Including Refills

Rank: 5 out of 74

$1.64M Total Retail Price of All Prescriptions

Rank: 6 out of 74

1,349 Patients Receiving at Least One Drug in Part D
77% Patients 65 Years and Older
1% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in Puerto Rico
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

1% of this provider’s 1,349 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Brand Name Drugs

31% of this provider’s prescriptions were for brand-name drugs, compared to an average of 30%.

Prescription Price

$112 was the average price of a prescription from this provider, compared to $118 among peers.

Prescriptions per Patient

11 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in Puerto Rico
DONEPEZIL HCL 1,752 1,675 337 1 1
NAMENDA 1,573 1,509 271 2 2
GABAPENTIN 958 529 241 3 3
CLONAZEPAM 704 596 141 B 4 7
CARBIDOPA-LEVODOPA 484 430 73 5 5
GALANTAMINE HBR 434 406 75 6 4
EXELON 326 321* 58 7 6
CLOPIDOGREL 309 274 72 8 13
SERTRALINE HCL 308 270 64 9 11
PRAMIPEXOLE DIHYDROCHLORIDE 283 236 42 10 10
DICLOFENAC POTASSIUM 264 116 88 11 28
LYRICA 237 144 41 12 15
CITALOPRAM HBR 206 166 48 13 14
LEVETIRACETAM 187 121 35 14 8
QUETIAPINE FUMARATE 175 175 29 A 15 9
CARBIDOPA-LEVODOPA-ENTACAPONE 173 159 26 16 32
PAROXETINE HCL 159 117 28 17 39
NABUMETONE 156 58 46 18 31
OMEPRAZOLE 156 92 35 18 37
SIMVASTATIN 155 109 25 20 20
PRIMIDONE 148 125 28 21 18
TRAMADOL HCL-ACETAMINOPHEN 140 97 54 22 16
TIZANIDINE HCL 139 42 52 23 12
FLUOXETINE HCL 136 114 22 24 70
ROPINIROLE HCL 127 122* 18 25 34
ZOLPIDEM TARTRATE 124 95 28 26 27
OXCARBAZEPINE 119 71 20 27 38
RANITIDINE HCL 116 86 32 28 24
AMANTADINE 111 106* 19 29 41
DILANTIN* 110 71 19 30 40
RIVASTIGMINE 109 109 14 31 42
AMITRIPTYLINE HCL 107 62 29 R 32 17
BACLOFEN 100 25 20 33 35
CARBIDOPA-LEVODOPA ER 95 76 18 34 23
LAMOTRIGINE 94 41 12 35 19
RISPERIDONE 90 85* 17 A 36 25
TEMAZEPAM 82 59 19 B 37 43
TRAMADOL HCL 80 24 25 38 29
LORAZEPAM 79 55 17 B 39 76
SELEGILINE HCL 77 <11 <11 40 59
ALPRAZOLAM 76 59 13 B 41 44
NORTRIPTYLINE HCL 76 60 27 41 46
ETODOLAC 73 25 23 43 30
PHENOBARBITAL 71 <11 <11 R 44 57
ENTACAPONE 70 57 13 45 133
PREDNISONE 65 60* 23 46 89
MELOXICAM 64 12 31 47 52
SYNTHROID 64 50 18 47 56
AMLODIPINE BESYLATE 64 49 13 47 60
CYMBALTA 63 <11 <11 50 21
TEGRETOL XR 60 <11 <11 51 97
LEVOTHYROXINE SODIUM 59 54* 15 52 63
TOPIRAMATE 54 <11 <11 53 22
KEPPRA 53 <11 <11 54 84
NAPROXEN 51 26 15 55 88
IRBESARTAN 50 37 11 56 110
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 9, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.